Hair growth pipeline (2026)

Key takeaways

• Nothing in the pipeline has yet beaten the current standard (minoxidil, finasteride and dutasteride, light and needling procedures, transplants) in a published, peer-reviewed, controlled trial for pattern hair loss.
• Closest to market for pattern hair loss: extended-release oral minoxidil (VDPHL01) from Veradermics, with phase 3 trials running in men and women, and sublingual minoxidil (phase 3 completed May 2026, no results posted). Both are new forms of an old drug. See minoxidil forms compared.
• Most interesting new mechanism: PP405, which wakes follicle stem cells. Phase 2a showed no blood absorption and company-reported density gains in men with more hair loss; a 600-man phase 2/3 began enrolling in September 2026 (trial record).
• Biologics: the prolactin-receptor antibodies HMI-115 (phase 2 done, results not public) and Absci's ABS-201 (early trial, interim hair data promised late 2026, full data early 2027).
• Autoimmune alopecia areata is far ahead of pattern hair loss: three JAK inhibitors are approved and upadacitinib is under review. See JAK inhibitors and hair.
• Failures matter: setipiprant and SM04554 both failed against placebo in humans, and bimatoprost on the scalp failed too (bimatoprost). Mouse and dish results rarely transfer.
• Be careful with early company numbers: most phase 2 headlines come from press releases, small subgroups or registry entries, not peer-reviewed papers.

The science

Pattern hair loss (androgenetic alopecia)

Antiandrogen candidates such as clascoterone and pyrilutamide are covered with the other androgen-pathway drugs.

Failed human trials worth knowing

Preclinical science that may become drugs

• UK-5099 (lactate and stem cell activation, the basis of PP405-type approaches), WAY-316606 (SFRP1), PTD-DBM (CXXC5), thymosin beta-4 and valproic acid, the only Wnt activator with a small positive human trial.

Alopecia areata and other autoimmune hair loss

• Upadacitinib: FDA submission in April 2026 and EMA review; at least 80% scalp hair at week 24 in 45% (15 mg) and 55% (30 mg) (Mostaghimi 2026).
• Other JAK candidates (jaktinib, ivarmacitinib), the anti-IL-7 receptor antibody bempikibart, dupilumab, ritlecitinib in moderate disease and topical delgocitinib in frontal fibrosing alopecia are in trials; we have not read their results.

What it means by hair profile

• Almost all pattern-hair-loss candidates enrol men with Norwood IV to V loss or mixed groups. Women have fewer trials; the women's VDPHL01 phase 3 and an oral minoxidil 1 mg trial are exceptions.
• Mechanisms that do not depend on androgens (stem-cell activation, prolactin-receptor blockade, minoxidil delivery) may suit women and people who cannot take finasteride or dutasteride, but no data prove that.
• Hair type (curl pattern, thickness) is not stratified in any registered trial found.

Myths and facts

• Myth: a positive phase 2 means it works. Fact: setipiprant and SM04554 reached phase 2 on good lab data and showed nothing in humans.
• Myth: peptides and research chemicals bought online (TB-500, WAY-316606, UK-5099, PTD-DBM) are early access to the pipeline. Fact: they are unapproved research chemicals with no human hair data.
• Myth: the pipeline will replace finasteride and minoxidil soon. Fact: every serious candidate is being added to, or measured against, those drugs.

Practical recommendations

• Use proven treatments now (minoxidil, finasteride) and watch for 2026 to 2027 readouts: VDPHL01 phase 3, PP405 phase 2/3 (primary completion December 2027), ABS-201 interim data and the upadacitinib FDA decision for alopecia areata.
• Joining a registered trial is the legitimate route to experimental drugs; ClinicalTrials.gov lists them.

Bottom line

The pipeline is promising but unproven; most numbers are company-reported. Treat anything not yet approved as information, not advice. Discuss with a doctor.